SI2948777T1 - Dipeptidno ponavljajoči se proteini kot terapevtski cilj pri nevrodegenerativnih boleznih s ponavljajočo ekspanzijo heksanukleotida - Google Patents

Dipeptidno ponavljajoči se proteini kot terapevtski cilj pri nevrodegenerativnih boleznih s ponavljajočo ekspanzijo heksanukleotida

Info

Publication number
SI2948777T1
SI2948777T1 SI201431324T SI201431324T SI2948777T1 SI 2948777 T1 SI2948777 T1 SI 2948777T1 SI 201431324 T SI201431324 T SI 201431324T SI 201431324 T SI201431324 T SI 201431324T SI 2948777 T1 SI2948777 T1 SI 2948777T1
Authority
SI
Slovenia
Prior art keywords
repeat
dipeptide
neurodegenerative diseases
therapeutic target
hexanucleotide
Prior art date
Application number
SI201431324T
Other languages
English (en)
Inventor
Dieter Edbauer
Christian Haass
Shih-Ming Weng
Kohji Mori
Thomas Arztberger
Elisabeth Kremmer
Original Assignee
Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/000190 external-priority patent/WO2014114303A1/en
Application filed by Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V filed Critical Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V
Publication of SI2948777T1 publication Critical patent/SI2948777T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201431324T 2013-01-22 2014-01-22 Dipeptidno ponavljajoči se proteini kot terapevtski cilj pri nevrodegenerativnih boleznih s ponavljajočo ekspanzijo heksanukleotida SI2948777T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2013/000190 WO2014114303A1 (en) 2013-01-22 2013-01-22 Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
EP13185419 2013-09-20
EP14701089.6A EP2948777B1 (en) 2013-01-22 2014-01-22 Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
PCT/EP2014/051204 WO2014114660A1 (en) 2013-01-22 2014-01-22 Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion

Publications (1)

Publication Number Publication Date
SI2948777T1 true SI2948777T1 (sl) 2019-11-29

Family

ID=49999965

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431324T SI2948777T1 (sl) 2013-01-22 2014-01-22 Dipeptidno ponavljajoči se proteini kot terapevtski cilj pri nevrodegenerativnih boleznih s ponavljajočo ekspanzijo heksanukleotida

Country Status (13)

Country Link
US (1) US10066007B2 (sl)
EP (2) EP2948777B1 (sl)
CY (1) CY1122079T1 (sl)
DK (1) DK2948777T3 (sl)
ES (1) ES2744804T3 (sl)
HR (1) HRP20191608T1 (sl)
HU (1) HUE046434T2 (sl)
LT (1) LT2948777T (sl)
PL (1) PL2948777T3 (sl)
PT (1) PT2948777T (sl)
RS (1) RS59283B1 (sl)
SI (1) SI2948777T1 (sl)
WO (1) WO2014114660A1 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2730677C2 (ru) 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Соединение для модуляции экспрессии гена c9orf72 и его применение
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
DK2906696T4 (da) 2012-10-15 2023-02-27 Ionis Pharmaceuticals Inc Fremgangsmåder til modulering af c9orf72-ekspression
US10066007B2 (en) * 2013-01-22 2018-09-04 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
EP2948471A4 (en) 2013-01-24 2016-08-10 Mayo Foundation METHOD AND MATERIALS FOR DETECTING POSITIVE FRONTOTEMPORAL PAPER DEGENERATION BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION OR AMYOTROPHATE LATERAL SCLEROSIS BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION
EP2970884A4 (en) 2013-03-14 2016-11-02 Univ Florida PROTEINS CONTAINING DIAMINATE CARBOXYLIC ACID REPETITIONS ASSOCIATED WITH ALS
SG11201602597YA (en) 2013-10-11 2016-05-30 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
SG10201902850TA (en) * 2014-09-30 2019-04-29 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
SG11201708468YA (en) * 2015-04-16 2017-11-29 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
AU2017246643B2 (en) 2016-04-04 2022-08-04 University Of Florida Research Foundation, Incorporated Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
JP6959632B2 (ja) * 2017-05-15 2021-11-02 学校法人近畿大学 筋萎縮性側索硬化症又は前頭側頭型認知症の予防又は治療剤
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. 神経障害の処置においてranタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
CN108795935B (zh) * 2018-05-23 2022-06-21 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫SjELAV-like 1基因的siRNA及其应用
CN113227116A (zh) * 2018-10-01 2021-08-06 联脑科学公司 针对源自c9orf72二肽重复蛋白的肽免疫原构建体
US20220202935A1 (en) * 2019-05-02 2022-06-30 Deutsches Zentrum Für Neurodegenrative Erkrankungen E.V.(Dzne) Immunogen for Preventing or Treating Familial Frontotemporal Dementia (FTD) and/or Amyotrophic Lateral Sclerosis (ALS)
EP4031562A4 (en) * 2019-09-20 2023-11-01 University of Florida Research Foundation, Incorporated DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES
CA3155639A1 (en) * 2019-09-23 2021-04-01 University Of Florida Research Foundation, Incorporated Vaccine therapy for ran protein diseases
WO2023244542A1 (en) * 2022-06-13 2023-12-21 Yeefan Med Inc Methods for detecting b-isox precipitates or captured proteins as biofluid biomarkers
WO2024097756A1 (en) * 2022-11-01 2024-05-10 University Of Florida Research Foundation, Incorporated Interrupted ran proteins in disease
WO2024102988A1 (en) * 2022-11-11 2024-05-16 Mayo Foundation For Medical Education And Research Treating proteinopathies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143668A1 (en) 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
US20040102608A1 (en) 2002-05-13 2004-05-27 Cornell Research Foundation, Inc. Multiblock copolymers having improved mechanical properties
US8221969B2 (en) 2004-04-19 2012-07-17 Sanyo Chemical Industries, Ltd. Method of producing virus
WO2007108205A1 (ja) * 2006-03-17 2007-09-27 Sanyo Chemical Industries, Ltd. 細胞培養用担体
CA2757354A1 (en) 2009-04-02 2010-10-07 Laura P.W. Ranum Nucleotide repeat expansion-associated polypeptides and uses thereof
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
RU2730677C2 (ru) * 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Соединение для модуляции экспрессии гена c9orf72 и его применение
US10066007B2 (en) * 2013-01-22 2018-09-04 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion

Also Published As

Publication number Publication date
WO2014114660A1 (en) 2014-07-31
LT2948777T (lt) 2019-09-25
HRP20191608T1 (hr) 2019-12-13
EP3588091A1 (en) 2020-01-01
RS59283B1 (sr) 2019-10-31
PT2948777T (pt) 2019-09-26
EP2948777B1 (en) 2019-06-26
PL2948777T3 (pl) 2019-12-31
CY1122079T1 (el) 2020-11-25
EP2948777A1 (en) 2015-12-02
ES2744804T3 (es) 2020-02-26
US10066007B2 (en) 2018-09-04
DK2948777T3 (da) 2019-09-23
US20150361166A1 (en) 2015-12-17
HUE046434T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
SI2948777T1 (sl) Dipeptidno ponavljajoči se proteini kot terapevtski cilj pri nevrodegenerativnih boleznih s ponavljajočo ekspanzijo heksanukleotida
HK1219964A1 (zh) 治療性蛋白藥物物質的整合連續製造
IL245744A0 (en) Therapeutic peptides
HK1219983A1 (zh) 治療性肽
HK1214829A1 (zh) 治療肽
HK1221726A1 (zh) 炎性疾病中的 結合蛋白
HK1216159A1 (zh) 治療性融合蛋白
SG11201505198WA (en) Protein purification methods
GB201308057D0 (en) Protein
HK1220991A1 (zh) 用於增加的重組蛋白產生的製劑和方法
HK1214964A1 (zh) 製備包含治療性蛋白質的顆粒的方法
GB201401955D0 (en) Protein
GB201304973D0 (en) Recombinant protein
EP2978770A4 (en) REINFORCEMENT OF PROTEINS
GB201320209D0 (en) Improvements in or relating to protein Micro-nets
GB201804143D0 (en) Human target II
EP2996684A4 (en) THERAPEUTIC PROCEDURES
GB201302030D0 (en) Protein
GB201302031D0 (en) Protein
GB201301072D0 (en) Therapeutic Moisturiser
GB201300778D0 (en) Therapeutic moisturiser
GB201305073D0 (en) Therapeutic means
GB201309967D0 (en) Therapeutic combinations
GB201302274D0 (en) Therapeutic and diagnositic target